sigma gains interim supply to indy chemists

It seems in the pharmaceutical supply wars, SIP has gone gently, whereas API has gone hardcore:

http://archive.traveldaily.com.au/PD/2011/Apr11/pd110411.pdf

Thanks to fdKen for this article posted on the API thread.

Also, AFR Street Talk just put up this article about the above:

http://afr.com.au/p/opinion/api_prepares_to_face_bullying_claims_hFchzkx7G6o70HMu269mBJ

Non-members of AFR online can get two weeks free trial if you chuck in your credit card details and cancel before the two weeks is up.

The above is not meant to be a downramp of API (given my expressed thoughts that I may buy API later down the track). As for now, it may be that SIP will get more market share. I'm glad I hold SIP at this point and not API. We also need buyers to knock off the overhang brought about by this special dividend. If SIP get formal agreements with Chemists, let's hope they put out a good ANN. Until then, the above media will have to do.